Comparative in Vitro Activities of Sparfloxacin (CI-978; AT-4140) and Other Antimicrobial Agents Against Staphylococci, Enterococci, and Respiratory Tract Pathogens

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1990 Nov 1

PMID 2127351

Citations 10

Authors

A E Simor

S A Fuller

D E Low

Affiliations

Soon will be listed here.

Abstract

The in vitro activity of sparfloxacin (CI-978; AT-4140) was compared with those of other antimicrobial agents against isolates of staphylococci, enterococci, and various respiratory tract pathogens. Sparfloxacin was the most active drug tested against staphylococci (MIC for 90% of the strains tested [MIC90], 0.125 micrograms/ml) and enterococci (MIC90, 1.0 microgram/ml). It was also active against Haemophilus influenzae (MIC90, less than or equal to 0.06 microgram/ml), Moraxella (Branhamella) catarrhalis (MIC90, 0.125 microgram/ml), Streptococcus pneumoniae (MIC90, 0.5 microgram/ml), and Streptococcus pyogenes (MIC90, 1.0 microgram/ml).

Citing Articles

Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Goa K, Bryson H, Markham A Drugs. 1997; 53(4):700-25.

PMID: 9098667 DOI: 10.2165/00003495-199753040-00010.

Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.

Trautmann M, Ruhnke M, Borner K, Wagner J, Koeppe P Antimicrob Agents Chemother. 1996; 40(3):776-9.

PMID: 8851610 PMC: 163197. DOI: 10.1128/AAC.40.3.776.

Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.

Ritz M, Lode H, Fassbender M, Borner K, Koeppe P, Nord C Antimicrob Agents Chemother. 1994; 38(3):455-9.

PMID: 8203837 PMC: 284479. DOI: 10.1128/AAC.38.3.455.

New quinolones and gram-positive bacteria.

Piddock L Antimicrob Agents Chemother. 1994; 38(2):163-9.

PMID: 8192436 PMC: 284419. DOI: 10.1128/AAC.38.2.163.

Sutton L, Jones R J Clin Microbiol. 1995; 33(1):146-8.

PMID: 7699031 PMC: 227897. DOI: 10.1128/jcm.33.1.146-148.1995.

References

Wolfson J, Hooper D . The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985; 28(4):581-6. PMC: 180310. DOI: 10.1128/AAC.28.4.581. View

Hooper D, Wolfson J . The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985; 28(5):716-21. PMC: 176369. DOI: 10.1128/AAC.28.5.716. View

Auckenthaler R, Pechere J . In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother. 1986; 17 Suppl B:29-39. DOI: 10.1093/jac/17.suppl_b.29. View

King A, Phillips I . The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother. 1986; 18 Suppl D:1-20. DOI: 10.1093/jac/18.supplement_d.1. View

Fass R . Treatment of skin and soft tissue infections with oral ciprofloxacin. J Antimicrob Chemother. 1986; 18 Suppl D:153-7. DOI: 10.1093/jac/18.supplement_d.153. View

Smith G, Leyland M, Farrell I, Geddes A . Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. J Antimicrob Chemother. 1986; 18 Suppl D:165-74. DOI: 10.1093/jac/18.supplement_d.165. View

Greenberg R, Kennedy D, Reilly P, Luppen K, Weinandt W, Bollinger M . Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother. 1987; 31(2):151-5. PMC: 174681. DOI: 10.1128/AAC.31.2.151. View

Garlando F, Rietiker S, Tauber M, Flepp M, Meier B, Luthy R . Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother. 1987; 31(2):354-6. PMC: 174727. DOI: 10.1128/AAC.31.2.354. View

Mulligan M, Ruane P, Johnston L, Wong P, Wheelock J, MacDonald K . Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med. 1987; 82(4A):215-9. View

10.

Smith R, Baltch A, Hammer M, CONROY J . In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains. Antimicrob Agents Chemother. 1988; 32(9):1450-5. PMC: 175890. DOI: 10.1128/AAC.32.9.1450. View

11.

Piercy E, Barbaro D, Luby J, Mackowiak P . Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 1989; 33(1):128-30. PMC: 171438. DOI: 10.1128/AAC.33.1.128. View

12.

Neu H, Novelli A, Chin N . Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother. 1989; 33(7):1036-41. PMC: 176058. DOI: 10.1128/AAC.33.7.1036. View

13.

Cooper B, Lawlor M . Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med. 1989; 87(4):475. DOI: 10.1016/s0002-9343(89)80838-1. View

14.

Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, Sakaguchi Y . In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989; 33(8):1167-73. PMC: 172618. DOI: 10.1128/AAC.33.8.1167. View

15.

Wolfson J, Hooper D . Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989; 2(4):378-424. PMC: 358131. DOI: 10.1128/CMR.2.4.378. View

16.

Kojima T, Inoue M, Mitsuhashi S . In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989; 33(11):1980-8. PMC: 172799. DOI: 10.1128/AAC.33.11.1980. View

17.

Nakamura S, Kurobe N, Ohue T, Hashimoto M, Shimizu M . Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother. 1990; 34(1):89-93. PMC: 171525. DOI: 10.1128/AAC.34.1.89. View

18.

Jones R, Barry A . In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990; 34(2):306-13. PMC: 171578. DOI: 10.1128/AAC.34.2.306. View

19.

Mazzulli T, Simor A, Jaeger R, Fuller S, Low D . Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990; 34(3):467-9. PMC: 171616. DOI: 10.1128/AAC.34.3.467. View